Sixty Percent of Surveyed Type 2 Diabetes Patients in the U.S. Who Use Insulin Indicate They Would Request a Switch to a Less Expensive Biosimilar Insulin if Such an Agent Became Available Most Surveyed Insulin Users Also Take at Least One Oral Antidiabetic, Resulting In Multiple Monthly Copayments, According to a New Report from Decision Resources
BURLINGTON, Mass., Dec. 23, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.
The new Patient Forum report entitled Patient Forum in Type 2 Diabetes: Patients' resistance to injectable agents may cause challenges for emerging GLP-1 analogues finds that although most surveyed type 2 diabetes patients indicate that they have some form of prescription coverage associated with their insurance, patients taking insulin report that they feel their disease is a greater financial burden compared to other patient segments. The majority of surveyed insulin users indicate they are also taking at least one oral antidiabetic, resulting in multiple copayments each month, increasing the monthly out-of-pocket cost for these patients.
"In addition, since patients who take insulin are generally advised to check their blood glucose at least twice each day, the cost of the necessary equipment such as test strips and glucose meters also contributes to a greater financial burden for insulin patients," said Decision Resources Program Manager Jennifer Moniz Carpenter, M.B.A.
Surveyed users of Amylin/Eli Lilly's Byetta are the most likely to request a switch to an agent that is injected once a week or once a month, suggesting that these patients may request a switch to an emerging GLP-1 analogue with improved dosing if they become aware of the drug.
"Amylin and Eli Lilly may be able to avoid loss of sales to other emerging GLP-1 analogues by campaigning for physicians to switch current Byetta users to the extended-release formulation, Bydureon, when the drug becomes available," Ms. Moniz Carpenter said.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
SOURCE Decision Resources